Vol. 6 No. 7 (2026): July
Reimbursement Reviews

Evolocumab

decorative image of the issue cover

Published July 10, 2026

Key Messages

  • Reimbursement reviews of drugs later in the life cycle include a comprehensive assessment of clinical value, unmet clinical need, distinct social and ethical considerations, economic considerations, and impacts on the health systems.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial drug plans and cancer agencies.
  • This review assesses Evolocumab, 140 mg in 1.0 mL (140 mg/mL), 420 mg in 3.5 mL (120 mg/mL), solution for injection, subcutaneous injection.
  • Indication under consideration for reimbursement: Evolocumab is indicated as an adjunct to diet and other LDL-C–lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in adult and pediatric patients aged 10 years and older with HoFH who require additional lowering of LDL-C.